Chron­ic wound biotech rais­es $26M in Se­ries D to ex­pand blood clot prod­ucts

Wound care com­pa­ny Red­Dress, whose prod­ucts heal chron­ic wounds us­ing the pa­tient’s own blood, has raised $26 mil­lion in a Se­ries D fund­ing round. The plan is to use the mon­ey to ex­pand use of its tech in the US, en­ter more glob­al part­ner­ships and move in­to oth­er con­di­tions.

This lat­est round of fund­ing brings the Is­rael-based com­pa­ny’s to­tal haul to $43 mil­lion. CEO Alon Kush­nir told End­point News that they’ve been able to at­tract in­vestors be­cause Red­Dress’s prod­ucts, Acti­Graft and Acti­Graft+, have al­ready been cleared by the FDA, com­mer­cial­ized and come with ro­bust da­ta be­hind them.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN